Close

AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review

December 9, 2016 10:08 AM EST Send to a Friend
(Updated - December 9, 2016 10:13 AM EST)AstraZeneca (NYSE: AZN) and its global biologics research and development arm, MedImmune, today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login